[Mucormycosis caused by Rhizopus oryzae in a patient with atypical diabetes].
Alvarez-Alvarez
Carlos
C
Rodríguez-Conde
Irene
I
Hortas-Guldrís
Mario
M
San Miguel-Fraile
Pilar
P
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D044383:Black People / Q000235:genetics; D003131:Combined Modality Therapy; D003646:Debridement; D003924:Diabetes Mellitus, Type 2 / Q000145:classification / Q000150:complications* / Q000235:genetics; D016883:Diabetic Ketoacidosis / Q000150:complications; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007262:Infusions, Intravenous; D008081:Liposomes / Q000008:administration & dosage; D008875:Middle Aged; D009091:Mucormycosis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D012074:Remission Induction; D012233:Rhizopus / Q000302:isolation & purification*; D012852:Sinusitis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery
D000935:Antifungal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B